1299607-55-8

Basic information

• Product Name: 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine;5-Bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylic acid 1,1-dimethylethyl ester;tert-butyl 5-bromopyrazolo[3,4-b]pyridine-1-carboxylate
• CAS NO: 1299607-55-8
• Molecular Formula: C11H12BrN3O2
• Molecular Weight: 298.13588
• Mol File: 1299607-55-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 371.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.04±0.30(Predicted)
• CAS DataBase Reference: 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine(1299607-55-8)
• EPA Substance Registry System: 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine(1299607-55-8)

Safety Data

• Hazardous Substances Data: 1299607-55-8(Hazardous Substances Data)

Usage

General Description

1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine is a chemical compound with the molecular formula C11H13BrN4O2. It is a pyrazole derivative that contains a Boc (tert-butoxycarbonyl) protecting group and a bromine atom. 1-Boc-5-broMo-1H-pyrazolo[3,4-b]pyridine has potential applications in medicinal chemistry and drug discovery, particularly in the development of new pharmaceuticals. It may also be used as a building block for the synthesis of other organic compounds with biological activity. Additionally, the bromine atom in its structure may enable it to participate in various chemical reactions, making it a versatile and valuable intermediate for organic synthesis.

Upstream product

• 875781-17-2 5-bromo-7-azaindazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 916326-31-3 tert-butyl 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 
• 68-12-2 N,N-dimethyl-formamide 
• 875781-18-3 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine 

Relevant articles and documents

PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Discovery of 6′-chloro-N-methyl-5’-(phenylsulfonamido)-[3,3′-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium

Starting from a bipyridine-sulfonamide scaffold, medicinal chemistry optimization leads to the discovery of a novel Plasmodium falciparum PI4K kinase (PfPI4K) inhibitor compound 15g (CHMFL-PI4K-127, IC50: 0.9 nM), which exhibits potent activity against 3D7 Plasmodium falciparum (P. falciparum) (EC50: 25.1 nM). CHMFL-PI4K-127 displays high selectivity against PfPI4K over human lipid and protein kinase. In addition, it exhibits EC50 values of 23–47 nM against a panel of the drug-resistant strains of P. falciparum. In vivo, the inhibitor demonstrates the favorable pharmacokinetic properties in both rats and mice. Furthermore, oral administration of CHMFL-PI4K-127 exhibits the antimalaria efficacy in both blood stage (80 mg/kg) and liver stage (1 mg/kg) of Plasmodium in infected rodent model. The results suggest that CHMFL-PI4K-127 might be a new potential drug candidate for malaria.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.